Adverse events during the titration phase of interferon-beta in remitting-relapsing multiple sclerosis are not predicted by body mass index nor by pharmacodynamic biomarkers.

Muñoz, Delicias

Adverse events during the titration phase of interferon-beta in remitting-relapsing multiple sclerosis are not predicted by body mass index nor by pharmacodynamic biomarkers. [electronic resource] - BMC neurology Jul 2013 - 82 p. digital

Publication Type: Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't

1471-2377

10.1186/1471-2377-13-82 doi


2',5'-Oligoadenylate Synthetase--metabolism
Body Mass Index
Female
Follow-Up Studies
Humans
Immunologic Factors--adverse effects
Interferon-beta--adverse effects
Kaplan-Meier Estimate
Male
Multiple Sclerosis, Chronic Progressive--drug therapy
Neopterin--metabolism
Predictive Value of Tests
Retrospective Studies
Treatment Outcome
beta 2-Microglobulin--metabolism